维普期刊资源整合服务平台（V6.5）

136篇 您的检索式：作者名="Richeldi"

选中清除导出查看参考文献查看引证文献引用追踪共7页首页上一页第1页下一页末页 /7 跳转

	题名	作者	年代	出处	被引量
1	尼达尼布联合吡非尼酮治疗特发性肺纤维化的INJOURNEY研究显示文摘背景尼达尼布、吡非尼酮是现阶段临床上应用的抗纤维化药物,两者均可延缓特发性肺纤维化(IPF)患者的病情进展,两者的抗肺纤维化机制不同.但关于两者联合治疗IPF 的安全性、有效性方面的研究数量有限.为此,开展了比较尼达尼布联合吡非尼酮与单药尼达尼布治疗IPF 的临床试验,以明确联合治疗组与单药治疗组之间在安全性、临床耐受性、药代动力学以及疗效方面的差异.方法本研究是为期12周的随机、开放临床试验,筛选≥40 岁、FVC%≥50%预计值的IPF 患者入组.	Vancheri C Kreuter M Richeldi L 孙宁新黄慧	2018	中华结核和呼吸杂志2018，41，5：	9
2	Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis显示文摘	Richeldi L Costabel U Selman M		0，，12：	2
3	Inactivation of polymerase inhibitors for Mycobacterium tuberculosis DNA amplification in sputum by using capture resin显示文摘	Amicosante M Richeldi L Trenti G	1995	J Clin Microbiol1995，33，3：	1
4	Triggering receptor ex- pressed on myeloid cells: role in the diagnosis of lung infections 显示文摘	Richeldi L Mariani M Losi M	2004	Eur Respir J2004，24，2：	1
5	Pirfenidone 显示文摘	Richeldi L Yasothan U Kirkpatriek P	2011	Nat RevDrug Discov2011，10，7：	1
6	Pirfenidone 显示文摘	Richeldi L Yasothan U Kirkpatrick P	2011	Nat Rev Drug Discov2011，10，7：	1
7	An update on the diagnosis of tuberculosis infection 显示文摘	Richeldi L	2006	Am J Respir Crit Care Med2006，174，7：	1
8	Idiopathic pulmonary fibrosis: current challenges and future perspectives显示文摘	Richeldi L	2013	Eur Respir Rev2013，22，128：	1
9	Emerging drugs for idiopathic pulmonary fibrosis 显示文摘	Selman M Pardo A Richeldi L	2011	Expert Opin Emerg Drugs2011，16，2：	1
10	Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis显示文摘	RICHELDI L COSTABEL U SELMAN M	2011	N Engl J Med2011，365，12：	1
11	Efficacy of a tyrosine kinase inhibitor in idiopathic pul- monary fibrosis显示文摘	Richeldi L	2011	N Engl J Med2011，365，：	1
12	Performance of tests for latent tuberculosis in different groups of immunocompromised patients显示文摘	Richeldi L Losi M D'Amico R		0，，01：	1
13	Efficacy and safety of nintedanib in idiopathic pulmo- nary fibrosis显示文摘	Richeldi L	2014	N Engl J Med2014，370，22：	1
14	Effi- cacy and safety of nintedanib in idiopathic pulmonary fi- brosis显示文摘	RICHELDI L DU BOIS R M RAGHU G	2014	N Engl J Med2014，370，22：	1
15	Corticosteroids for id- iopathic pulmonary fibrosis显示文摘	Richeldi L Davies HR Ferrara G	2003	Cochrane Database Syst Rev2003，3，00：	1
16	Design of the INPULSISTM trials:two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibro- sis 显示文摘	RICHELDI L COTTIN V FLAHERTY K R	2014	Respir Med2014，108，7：	1
17	Management of Multidrug-resistant Tuberculosis in Italy显示文摘	Ferrara G Richeldi L Bugiani M Cirillo D Besozzi G Nutini S Casali L Fiorentini F Codecasa LR Migliori GB	2005	Int J Tuberc Lung Dis2005，9，5：	1
18	Room size is themajor determinant for tuberculin conversion in health care workersexposed to a multidrug-resistant tuberculosis patient 显示文摘	Franchi A Richeldi L Parrinello G	2007	Int ArchOccup Environ Health2007，80，6：	1
19	Clinical trials of investigational agents for IPF: a re-view of a Cochrane report显示文摘	RICHELDI L	2013	Respir Res2013，14，1：	1
20	Lymphokines in crystal RG west JB weibel ER the lung :scientific foundations 2nd Philadelphia显示文摘	Fracheldi A Richeldi L	1997	Lippincott-Raven Publishers1997，12，3：	1

返回顶部每页显示：

共7页首页上一页第1页下一页末页 /7 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示